British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals (multiple letters) [1]

Lancet

Volumn 349, Issue 9068, 1997, Pages 1837-1839

  Payne, N ^a   Carey, P B ^a   Lloyd, J ^a   Timmins, D ^a   Brettle, R P ^a   Burns, S B ^a   Povey, S ^a   Leen, C L S ^a   Welsby, P D ^a   Harindra, V ^a   Gazzard, B G ^a   Moyle, G ^a  

^a Sheffield Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH CARE FINANCING; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOM; UNITED KINGDOM; ECONOMICS; NOTE; CD4 LYMPHOCYTE COUNT; IMMUNOLOGY; VIROLOGY; VIRUS LOAD; DRUG COMBINATION;

ANTI-HIV AGENTS; DRUG COSTS; GREAT BRITAIN; HIV SEROPOSITIVITY; HUMANS; PRACTICE GUIDELINES AS TOPIC; CD4 LYMPHOCYTE COUNT; VIRAL LOAD; DRUG THERAPY, COMBINATION;

EID: 0031007534     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)26025-3     Document Type: Letter

References (0)